Developer docs
API playgroundTry for free, no card

Search company profiles

LayerBio

Full company profile

uuid0006y1d

Namestring
LayerBio
Legal namestring
LayerBio, Inc.
Websiteurl
layerbio.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

LayerBio, Inc. is a privately held, clinical-stage biotechnology company founded in 2013 as a spin-off from the laboratory of Dr. Paula Hammond at MIT. The company develops proprietary drug delivery platforms for ophthalmology, anchored by two registered technologies: PolyNet™, a tunable network polymer-based, bio-erodible drug delivery system, and OcuRing™, a bioerodible sustained-release implant applied to the haptic of a standard intraocular lens (IOL) at the time of cataract surgery to continuously release medication postoperatively. The lead clinical asset, OcuRing™-K, is a ketorolac-loaded OcuRing implant intended to deliver sustained postoperative pain and inflammation control after cataract surgery and to enable drop-less cataract surgery by eliminating the need for patient-administered topical eye drops. LayerBio is also advancing a sustained-release travoprost formulation for glaucoma using the PolyNet platform, and previously explored wound care and tendon repair applications.

The company operates from the greater Boston area (Medford and Lexington, Massachusetts) with a small team of 1–10 employees and is led by founder and CEO Dr. Ken Mandell (MD, PhD), with co-founder Dr. Paula Hammond serving as a director. To date, LayerBio has funded its research and development primarily through approximately $8 million in non-dilutive grants, including a $3 million U.S. Department of Defense Technology/Therapeutic Development Award, a $1.2 million Phase 2 SBIR grant from the NIH National Eye Institute, NSF SBIR funding, and a Massachusetts Life Sciences Center Milestone Achievement Program grant. In August 2025, PRF Technologies Ltd. (NASDAQ:PRFX, formerly PainReform Ltd.) acquired a majority stake in LayerBio, making it a majority-owned subsidiary and positioning the company to leverage a public-company platform for future capital and commercialization.

LayerBio is pre-revenue and does not currently sell products; its business model contemplates future one-time licensing and direct product sales to hospitals, ambulatory surgery centers, and ophthalmology practices once OcuRing-K and related candidates receive regulatory approval. The company's go-to-market approach is built around scientific engagement with ophthalmologists, cataract surgeons, and key opinion leaders through major industry conferences (AAO, ASCRS, ARVO, OIS, Eyecelerator) and peer-reviewed publications, with FDA IND clearance for the OcuRing-K Phase II trial granted in April 2026 following a clean Phase I safety readout.

Short descriptiontext

LayerBio is a pre-revenue, clinical-stage ophthalmology biotech developing proprietary bioerodible drug delivery platforms (OcuRing™ and PolyNet™) for drop-less cataract surgery and sustained-release glaucoma treatment, and is a majority-owned subsidiary of PRF Technologies (NASDAQ:PRFX).

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersArlington, United States
HQ citystring
Arlington
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
ophthalmic drug delivery, sustained-release implants, intraocular lens technology, cataract surgery devices, biocompatible polymers
Industry3 codes
PRIMARYHLAHAIAL
Ocular Drug Delivery Devices (Eye Droppers/Inserts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAHAJAH
Cataract Surgery Systems & IOLs (Phaco Systems, IOLs, Intraoperative Aberrometry, Viscoelastics)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
NAICS code2 codes
  • Ophthalmic Goods Manufacturing339115
  • Surgical and Medical Instrument Manufacturing339112
SIC code3 codes
  • Ophthalmic Goods3851
  • Surgical & Medical Instruments & Apparatus3841
  • Pharmaceutical Preparations2834
Product category
Ophthalmic Drug Delivery
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Product Sales (Future)
TypeOne Time License
Description

As a clinical-stage company, LayerBio does not currently generate revenue. Future revenue is expected from commercializing its OcuRing™ product platform for cataract surgery and other ophthalmic applications following regulatory approval.

globenewswire.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1OcuRing™
Description

Bioerodible sustained-release implant applied to the haptic of an intraocular lens (IOL) for use in cataract surgery. Continuously releases medications for treatment and prevention of postoperative complications.

layerbio.com
+1 more record
Core offering1 text field

LayerBio is a clinical-stage biotechnology company developing proprietary bioerodible sustained-release drug delivery platforms for ophthalmology. Its lead product OcuRing™-K is a drop-less ketorolac implant applied to intraocular lenses during cataract surgery to manage postoperative pain and inflammation, with a broader pipeline including sustained-release glaucoma formulations built on its PolyNet™ polymer delivery platform.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • No treatment-emergent adverse events reported in Phase I clinical study
+3 more records
Product overview1 text field

LayerBio is a clinical-stage biotechnology company developing novel drug delivery products for ophthalmology. The company's portfolio centers on its proprietary PolyNet™ platform technology, which enables tunable, sustained-release drug delivery from bio-erodible polymers. The lead product is OcuRing™-K, a bio-erodible sustained-release ketorolac implant for post-cataract surgery pain and inflammation management. The OcuRing™ platform is designed to be applied to standard intraocular lenses (IOLs) during cataract surgery, eliminating the need for postoperative eye drops. The company is also developing sustained-release formulations for glaucoma treatment using travoprost, as well as products for wound care and tendon repair.

Product and service4 records
1OcuRing™
CategoryOphthalmic Drug Delivery / Cataract Surgery Implant
Description

Bioerodible sustained-release implant applied to the haptic of an intraocular lens (IOL) for use in cataract surgery; once implanted, it continuously releases medications for treatment and prevention of postoperative complications. Designed for use with any standard IOL and standard surgical techniques.

2OcuRing™-K
CategoryOphthalmic Drug Delivery / Cataract Surgery Implant
Description

Drop-less, sustained-release ocular drug delivery platform delivering ketorolac intraoperatively during cataract surgery to manage postoperative pain and inflammation, eliminating the need for patient-administered topical eye drops. IND cleared for Phase II trial in April 2026.

3PolyNet™
CategoryDrug Delivery Technology Platform
Description

Proprietary network polymer-based drug delivery platform enabling tunable control of drug release from a biocompatible, bio-erodible polymer system with a variety of medication classes for glaucoma and other ophthalmic indications.

4Sustained-Release Glaucoma Formulation (Travoprost)
CategoryOphthalmic Drug Delivery / Glaucoma Therapy
Description

Extended-release formulation of the glaucoma drug travoprost using PolyNet™ technology, designed to lower intraocular pressure to therapeutic levels for longer than six months.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global leader in cataract surgery devices including IOLs and surgical equipment, and a major ophthalmic pharmaceutical company. Comparable because it controls the standard IOLs that OcuRing is designed to attach to and could in-license or replicate LayerBio's drug-eluting IOL approach.

TypeEmerging player
Description

Ophthalmic company developing novel therapeutics for glaucoma and other eye diseases, with a sustained-release research program and established European ophthalmic commercial infrastructure. Comparable as a focused ophthalmic drug development peer.

TypeBroad incumbent
Description

Diversified ophthalmic company with a leading cataract/IOL franchise (e.g., enVista, Vitesse) and pharmaceutical eye-drop portfolio. Comparable as the incumbent whose installed IOL base LayerBio targets and whose eye-drop business a drop-less IOL would disrupt.

TypeBroad incumbent
Description

Global pharmaceutical company whose Allergan franchise markets leading ophthalmic pharmaceuticals and steroid eye drops used post-cataract surgery. Comparable as the incumbent whose steroid/NSAID drop franchise LayerBio's drop-less approach would directly compete with.

TypeEmerging player
Description

Clinical-stage biopharmaceutical company developing novel therapies for retinal eye diseases. Comparable as a similarly-sized, focused ophthalmic clinical-stage peer targeting differentiated indications in vision care.

TypeDirect peer
Description

Develops sustained-release ocular drug delivery products including DURYSTA for glaucoma and YUTIQ for posterior segment inflammation. Comparable to LayerBio in targeting sustained-release ophthalmic drug delivery to eliminate topical drop dependence.

TypeDirect peer
Description

Ophthalmic medical technology company developing novel drug delivery platforms for glaucoma and other eye diseases, including sustained-release and procedural pharmaceutical delivery approaches. Comparable technology and target indications to LayerBio's PolyNet glaucoma program.

TypeEmerging player
Description

Clinical-stage ophthalmic company developing novel therapies for front and back of the eye using a proprietary mucus-penetrating particle delivery platform. Comparable as a small-cap ocular drug delivery peer advancing differentiated sustained-release formulations.

TypeDirect peer
Description

Clinical and commercial-stage company developing sustained-release ocular drug delivery platforms (e.g., DEXTENZA for post-surgical ocular inflammation and pain). Directly comparable to LayerBio's OcuRing-K as a drop-less, bioerodible ocular implant targeting the same post-cataract surgery indication.

TypeBroad incumbent
Description

Major IOL and cataract surgery franchise (TECNIS) within a global medtech conglomerate. Comparable as a dominant IOL manufacturer whose standard lenses OcuRing attaches to and whose surgical channel LayerBio would ultimately need to access.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

LayerBio

Ophthalmic Drug Deliverylayerbio.com

LayerBio is a pre-revenue, clinical-stage ophthalmology biotech developing proprietary bioerodible drug delivery platforms (OcuRing™ and PolyNet™) for drop-less cataract surgery and sustained-release glaucoma treatment, and is a majority-owned subsidiary of PRF Technologies (NASDAQ:PRFX).

What LayerBio does

LayerBio, Inc. is a privately held, clinical-stage biotechnology company founded in 2013 as a spin-off from the laboratory of Dr. Paula Hammond at MIT. The company develops proprietary drug delivery platforms for ophthalmology, anchored by two registered technologies: PolyNet™, a tunable network polymer-based, bio-erodible drug delivery system, and OcuRing™, a bioerodible sustained-release implant applied to the haptic of a standard intraocular lens (IOL) at the time of cataract surgery to continuously release medication postoperatively. The lead clinical asset, OcuRing™-K, is a ketorolac-loaded OcuRing implant intended to deliver sustained postoperative pain and inflammation control after cataract surgery and to enable drop-less cataract surgery by eliminating the need for patient-administered topical eye drops. LayerBio is also advancing a sustained-release travoprost formulation for glaucoma using the PolyNet platform, and previously explored wound care and tendon repair applications.

The company operates from the greater Boston area (Medford and Lexington, Massachusetts) with a small team of 1–10 employees and is led by founder and CEO Dr. Ken Mandell (MD, PhD), with co-founder Dr. Paula Hammond serving as a director. To date, LayerBio has funded its research and development primarily through approximately $8 million in non-dilutive grants, including a $3 million U.S. Department of Defense Technology/Therapeutic Development Award, a $1.2 million Phase 2 SBIR grant from the NIH National Eye Institute, NSF SBIR funding, and a Massachusetts Life Sciences Center Milestone Achievement Program grant. In August 2025, PRF Technologies Ltd. (NASDAQ:PRFX, formerly PainReform Ltd.) acquired a majority stake in LayerBio, making it a majority-owned subsidiary and positioning the company to leverage a public-company platform for future capital and commercialization.

LayerBio is pre-revenue and does not currently sell products; its business model contemplates future one-time licensing and direct product sales to hospitals, ambulatory surgery centers, and ophthalmology practices once OcuRing-K and related candidates receive regulatory approval. The company's go-to-market approach is built around scientific engagement with ophthalmologists, cataract surgeons, and key opinion leaders through major industry conferences (AAO, ASCRS, ARVO, OIS, Eyecelerator) and peer-reviewed publications, with FDA IND clearance for the OcuRing-K Phase II trial granted in April 2026 following a clean Phase I safety readout.

LayerBio firmographics

Firmographics
Name
LayerBio
Legal name
LayerBio, Inc.
Website
https://layerbio.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
1–10 employees
Short description
LayerBio is a pre-revenue, clinical-stage ophthalmology biotech developing proprietary bioerodible drug delivery platforms (OcuRing™ and PolyNet™) for drop-less cataract surgery and sustained-release glaucoma treatment, and is a majority-owned subsidiary of PRF Technologies (NASDAQ:PRFX).
Ownership category
akta.pro rank

LayerBio industry classification

Industry
Product category
Ophthalmic Drug Delivery
NAICS
Ophthalmic Goods Manufacturing (339115), Surgical and Medical Instrument Manufacturing (339112)
SIC
Ophthalmic Goods (3851), Surgical & Medical Instruments & Apparatus (3841), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAHAIAL
Ocular Drug Delivery Devices (Eye Droppers/Inserts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAHAJAH
Cataract Surgery Systems & IOLs (Phaco Systems, IOLs, Intraoperative Aberrometry, Viscoelastics)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals

Keywords

  • Ophthalmic drug delivery
  • Sustained-release implants
  • Intraocular lens technology
  • Cataract surgery devices
  • Biocompatible polymers

Where LayerBio is headquartered

Location

Headquarters

HQ city
Arlington
HQ country
United States
HQ region
North America

Offices2 records

Markets served

LayerBio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Product Sales (Future): As a clinical-stage company, LayerBio does not currently generate revenue. Future revenue is expected from commercializing its OcuRing™ product platform for cataract surgery and other ophthalmic applications following regulatory approval.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

LayerBio product offering

Product offering

Core offering

LayerBio is a clinical-stage biotechnology company developing proprietary bioerodible sustained-release drug delivery platforms for ophthalmology. Its lead product OcuRing™-K is a drop-less ketorolac implant applied to intraocular lenses during cataract surgery to manage postoperative pain and inflammation, with a broader pipeline including sustained-release glaucoma formulations built on its PolyNet™ polymer delivery platform.

Product overview

LayerBio is a clinical-stage biotechnology company developing novel drug delivery products for ophthalmology. The company's portfolio centers on its proprietary PolyNet™ platform technology, which enables tunable, sustained-release drug delivery from bio-erodible polymers. The lead product is OcuRing™-K, a bio-erodible sustained-release ketorolac implant for post-cataract surgery pain and inflammation management. The OcuRing™ platform is designed to be applied to standard intraocular lenses (IOLs) during cataract surgery, eliminating the need for postoperative eye drops. The company is also developing sustained-release formulations for glaucoma treatment using travoprost, as well as products for wound care and tendon repair.

Differentiator

Problem solved

Functional benefit

Brands

  • OcuRing™: Bioerodible sustained-release implant applied to the haptic of an intraocular lens (IOL) for use in cataract surgery. Continuously releases medications for treatment and prevention of postoperative complications.
  • PolyNet™

Products and services

  • OcuRing™ Bioerodible sustained-release implant applied to the haptic of an intraocular lens (IOL) for use in cataract surgery; once implanted, it continuously releases medications for treatment and prevention of postoperative complications. Designed for use with any standard IOL and standard surgical techniques.
  • OcuRing™-K Drop-less, sustained-release ocular drug delivery platform delivering ketorolac intraoperatively during cataract surgery to manage postoperative pain and inflammation, eliminating the need for patient-administered topical eye drops. IND cleared for Phase II trial in April 2026.
  • PolyNet™ Proprietary network polymer-based drug delivery platform enabling tunable control of drug release from a biocompatible, bio-erodible polymer system with a variety of medication classes for glaucoma and other ophthalmic indications.
  • Sustained-Release Glaucoma Formulation (Travoprost) Extended-release formulation of the glaucoma drug travoprost using PolyNet™ technology, designed to lower intraocular pressure to therapeutic levels for longer than six months.

Quantifiable outcome

  • No treatment-emergent adverse events reported in Phase I clinical study
  • +3 more outcomes

Companies that use LayerBio

Customer profile

Segments3 records

Ideal customer profiles2 records

LayerBio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

LayerBio partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves6 records

Expansion highlights4 records

LayerBio competitors and assessment

Company assessment

Broad incumbents

  • Alcon: Global leader in cataract surgery devices including IOLs and surgical equipment, and a major ophthalmic pharmaceutical company. Comparable because it controls the standard IOLs that OcuRing is designed to attach to and could in-license or replicate LayerBio's drug-eluting IOL approach.
  • Bausch + Lomb: Diversified ophthalmic company with a leading cataract/IOL franchise (e.g., enVista, Vitesse) and pharmaceutical eye-drop portfolio. Comparable as the incumbent whose installed IOL base LayerBio targets and whose eye-drop business a drop-less IOL would disrupt.
  • AbbVie (Allergan Aesthetics / Eye Care): Global pharmaceutical company whose Allergan franchise markets leading ophthalmic pharmaceuticals and steroid eye drops used post-cataract surgery. Comparable as the incumbent whose steroid/NSAID drop franchise LayerBio's drop-less approach would directly compete with.
  • Johnson & Johnson Vision: Major IOL and cataract surgery franchise (TECNIS) within a global medtech conglomerate. Comparable as a dominant IOL manufacturer whose standard lenses OcuRing attaches to and whose surgical channel LayerBio would ultimately need to access.

Emerging players

  • Nicox: Ophthalmic company developing novel therapeutics for glaucoma and other eye diseases, with a sustained-release research program and established European ophthalmic commercial infrastructure. Comparable as a focused ophthalmic drug development peer.
  • Opthea: Clinical-stage biopharmaceutical company developing novel therapies for retinal eye diseases. Comparable as a similarly-sized, focused ophthalmic clinical-stage peer targeting differentiated indications in vision care.
  • Kala Bio: Clinical-stage ophthalmic company developing novel therapies for front and back of the eye using a proprietary mucus-penetrating particle delivery platform. Comparable as a small-cap ocular drug delivery peer advancing differentiated sustained-release formulations.

Direct peers

  • EyePoint Pharmaceuticals: Develops sustained-release ocular drug delivery products including DURYSTA for glaucoma and YUTIQ for posterior segment inflammation. Comparable to LayerBio in targeting sustained-release ophthalmic drug delivery to eliminate topical drop dependence.
  • Glaukos Corporation: Ophthalmic medical technology company developing novel drug delivery platforms for glaucoma and other eye diseases, including sustained-release and procedural pharmaceutical delivery approaches. Comparable technology and target indications to LayerBio's PolyNet glaucoma program.
  • Ocular Therapeutix: Clinical and commercial-stage company developing sustained-release ocular drug delivery platforms (e.g., DEXTENZA for post-surgical ocular inflammation and pain). Directly comparable to LayerBio's OcuRing-K as a drop-less, bioerodible ocular implant targeting the same post-cataract surgery indication.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

LayerBio social profiles

Digital presence

LayerBio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

LayerBio leadership team

Management profile

Number of profiles

Profiles2 records

LayerBio funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

LayerBio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LayerBio

What does LayerBio do?

LayerBio is a clinical-stage biotechnology company developing proprietary bioerodible sustained-release drug delivery platforms for ophthalmology. Its lead product OcuRing™-K is a drop-less ketorolac implant applied to intraocular lenses during cataract surgery to manage postoperative pain and inflammation, with a broader pipeline including sustained-release glaucoma formulations built on its PolyNet™ polymer delivery platform.

Is LayerBio a public or private company?

LayerBio is a private company. It is classified as corporate owned and is currently operating.

When was LayerBio founded?

LayerBio was founded in 2013. It employs 1 to 10 people.

Where is LayerBio based?

LayerBio is headquartered in Arlington, United States, in the North America region.

How does LayerBio make money?

One revenue line is on record: product Sales (Future).

Who are LayerBio's main competitors?

Broad incumbents on record are Alcon, Bausch + Lomb, AbbVie (Allergan Aesthetics / Eye Care) and Johnson & Johnson Vision. Emerging players are Nicox, Opthea and Kala Bio. Direct peers are EyePoint Pharmaceuticals, Glaukos Corporation and Ocular Therapeutix.

Does LayerBio have an API?

No public API is recorded for LayerBio.

What industry is LayerBio in?

LayerBio's product category is Ophthalmic Drug Delivery. Its primary akta.pro industry code is HLAHAIAL, Ocular Drug Delivery Devices (Eye Droppers/Inserts), with a secondary code of HLAHAJAH, Cataract Surgery Systems & IOLs (Phaco Systems, IOLs, Intraoperative Aberrometry, Viscoelastics). Its NAICS code is 339115 and its SIC code is 3851.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Ophthalmology TimesLayerBio granted patent for novel drug delivery platformLayerBio Inc. announced the receipt of a patent for its OcuRing drug delivery platform, a bioerodible sustained-release technology designed for use with standard intraocular lenses in cataract surgery. The company states that this milestone supports the development of safer alternatives to topical eye drops by enabling direct drug release inside the eye to improve patient compliance and outcomes.BenzingaEXCLUSIVE: PRF Technologies Advances Drop-Less Drug For Cataract Surgery Pain - PRF Technologies (NASDAQ:The FDA cleared PRF Technologies Ltd.'s Investigational New Drug application for OcuRing-K, a bio-erodible intraocular ring delivering ketorolac directly to the surgical site, enabling a Phase 2 trial targeting pain and inflammation following cataract surgery. The company, alongside its majority-owned subsidiary LayerBio, Inc., expects to begin enrolling patients in the multi-center U.S. study in the second half of 2026. PRF Technologies is positioning OcuRing-K as a drop-less alternative to traditional post-operative eye drop regimens, with broader potential across its LayerBio platform for additional ophthalmic applications including NSAIDs, steroids, and anti-VEGF therapies.The Manila TimesPRF Technologies Provides Year-End 2025 Business Update Highlighting Strategic Progress Across Healthcare and AI-Driven Solar PlatformsPRF Technologies Ltd. completed two strategic acquisitions in 2025 — DeepSolar (AI-driven solar analytics, March 2025) and a majority stake in LayerBio (August 2025, adding the OcuRing™-K sustained-release ocular therapy platform) — repositioning itself as a diversified innovation platform spanning healthcare and renewable-energy analytics. OcuRing™-K advanced through preclinical and Phase I safety studies supporting progression toward a Phase II IND, while DeepSolar launched commercial offerings including Smart TDD, was accepted into the NVIDIA Connect Program, and signed its first SaaS agreement with Shikun & Binui Energy for a 71 MW solar project in Romania. The company reported a net loss of $4.8 million for 2025, down from $14.6 million in 2024, ending the year with approximately $4.1 million in cash and $4.0 million in gross proceeds from at-the-market issuances.GlobeNewswirePRF Technologies Provides Year-End 2025 Business Update Highlighting Strategic Progress Across Healthcare and AI-Driven Solar PlatformsPRF Technologies Ltd. reported substantial strategic progress for 2025, completing two acquisitions — DeepSolar for AI-driven solar analytics in March and a majority stake in LayerBio for ocular drug delivery in August — while advancing its OcuRing™-K through IND-supporting activities with favorable preclinical and Phase I safety data. DeepSolar has moved from acquisition to early commercial deployment, including a SaaS agreement with Shikun & Binui Energy for a 71 MW solar project in Romania, acceptance into the NVIDIA Connect Program, and its first patent filing. Financially, the company reduced its net loss to $4.8 million from $14.6 million, while ending 2025 with approximately $4.1 million in cash and positive working capital of approximately $2.0 million.The Manila TimesPainReform Ltd. Changes Name to PRF Technologies Ltd. Reflecting Expansion into Diversified Healthcare and AI-Driven Energy PlatformsPRF Technologies Ltd. (formerly PainReform Ltd.) announced a corporate name change following shareholder approval on January 6, 2026, marking a strategic shift from a single-product focus to a diversified innovation platform spanning specialty pharmaceuticals, drug-delivery technologies, and AI-driven renewable-energy analytics. The company's portfolio now includes three growth platforms: PRF-110 for postoperative pain relief, LayerBio's OcuRing™-K for cataract surgery, and DeepSolar's AI-powered solar asset management solutions. The company states this move is designed to build long-term value through diversification and reduced reliance on any single outcome, though the announcement acknowledges ongoing challenges including significant losses and the need for additional capital.SahmcapitalPainReform Ltd. Changes Name to PRF Technologies Ltd. Reflecting Expansion into Diversified Healthcare and AI-Driven Energy PlatformsPRF Technologies Ltd. (formerly PainReform Ltd.) completed a shareholder-approved corporate name change on January 6, 2026, reflecting its strategic shift from a single-product focus to a diversified innovation platform spanning specialty pharmaceuticals and AI-driven renewable-energy analytics. The company, which now trades under the Nasdaq ticker PRFX, has broadened its portfolio over 18 months through majority-owned subsidiary LayerBio in ophthalmology (with OcuRing™-K for post-cataract surgery therapy) and through DeepSolar, an AI-driven solar analytics and digital asset-management business.Stock TitanPRF Technologies name change marks diversificationPainReform Ltd. officially changed its name to PRF Technologies Ltd. following shareholder approval at its January 6, 2026 Annual General Meeting, with the Nasdaq ticker symbol remaining PRFX. The name change reflects the company's strategic shift from a single-product focus to a diversified innovation platform spanning specialty pharmaceuticals, advanced drug-delivery technologies, and AI-driven renewable-energy analytics. Over the past 18 months, the company has expanded its portfolio through majority ownership of LayerBio (ophthalmology via OcuRing™-K) and development of DeepSolar (AI-driven solar analytics), positioning itself for long-term growth across multiple high-growth markets.TipranksPainReform Rebrands as PRF Technologies to Reflect Expansion into Healthcare and AI-Driven EnergyPainReform Ltd. announced it changed its corporate name to PRF Technologies Ltd. on January 15, 2026, following shareholder approval at its January 6, 2026 annual general meeting. The rebranding reflects the company's expansion beyond a single-asset pain-treatment developer into a diversified platform encompassing LayerBio's OcuRing-K sustained-release ocular therapy for post-cataract surgery care and the DeepSolar AI-based solar analytics and forecasting business. PRF Technologies states it aims to reduce reliance on any single product while targeting large, high-growth markets in both specialty pharmaceuticals and renewable energy.NasdaqPainReform’s LayerBio’s Drop-Less OcuRing™-K Delivery Platform Demonstrates Favorable Safety Profile in Preclinical and Phase I Clinical StudiesPainReform Ltd. and its majority-owned subsidiary LayerBio, Inc. announced favorable safety data from preclinical rabbit studies and a Phase I clinical study for OcuRing™-K, a drop-less, sustained-release ocular drug delivery platform for cataract surgery, with no treatment-emergent adverse events or serious adverse events reported in either study. The consistent safety profile across animal models and human subjects supports the platform's advancement toward later-stage development and an Investigational New Drug (IND) submission in the United States. The company is advancing IND-enabling activities with preparation and development efforts underway for the next phase of clinical evaluation.YahooPainReform’s LayerBio’s Drop-Less OcuRing™-K Delivery Platform Demonstrates Favorable Safety Profile in Preclinical and Phase I Clinical StudiesPainReform Ltd. and its subsidiary LayerBio announced favorable safety data for their OcuRing-K drug delivery platform for cataract surgery, supporting progress toward IND submission. The platform showed no safety concerns in preclinical and Phase I clinical studies, demonstrating targeted, sustained ocular drug release with minimal adverse effects.